Liver Cancer Therapeutics Industry Revenue to Reach $5.45 Billion by 2029 with CAGR of 16.7% (2025–2029)
Claim 20% Off With Code ONLINE20 – Explore Market Reports Covering Trade Trends, Regulatory Changes, and Growth Insights
What Is the Projected Growth Rate of the Liver Cancer Therapeutics Market Through 2029?
The liver cancer therapeutics market size has grown rapidly in recent years. It will grow from $2.52 billion in 2024 to $2.94 billion in 2025 at a compound annual growth rate (CAGR) of 16.8%. The growth in the historic period can be attributed to increasing funding from government and non-profits, rising healthcare expenditure globally, expanding health insurance coverage in developing countries, aging global population, increasing prevalence of obesity and diabetes.
The liver cancer therapeutics market size is expected to see rapid growth in the next few years. It will grow to $5.45 billion in 2029 at a compound annual growth rate (CAGR) of 16.7%. The growth in the forecast period can be attributed to rising global incidence of liver cancer, high prevalence of hepatitis B and C infections, increase in alcohol-related liver disease, rising cases of non-alcoholic fatty liver disease, growing adoption of immunotherapy approaches. Major trends in the forecast period include integration of AI and ML in drug discovery, use of big data and real-world evidence in trials, development of advanced imaging technologies, adoption of minimally invasive diagnostic tools, telemedicine and digital health in oncology follow-up care.
Claim your free report sample now:
Which Drivers Are Positively Impacting the Liver Cancer Therapeutics Market?
The rise in incidence of hepatitis B infections is anticipated to fuel the growth of the liver cancer therapeutics market going forward. Hepatitis B infection refers to a viral disease caused by the hepatitis B virus (HBV) that primarily affects the liver and can lead to both short-term (acute) and long-term (chronic) health complications, including liver cancer. The rise in hepatitis B infections is partly driven by increasing injection drug use, which spreads the virus through the sharing of contaminated needles and syringes. Liver cancer therapeutics are required for hepatitis B infections, as chronic infection can lead to persistent liver inflammation and cellular damage, significantly increasing the risk of developing malignant liver conditions over time. For instance, in April 2024, according to a report published by the World Health Organization (WHO), a Switzerland-based intergovernmental organization, there were over 254 million hepatitis B-positive people in the world in 2022, and 1.2 million new cases were recorded. Furthermore, hepatitis B was responsible for 83% of the 1.3 million deaths related to viral hepatitis that occurred worldwide. Therefore, the rising incidence of hepatitis B infections will boost the growth of the liver cancer therapeutics market.
Which Are the Leading Segments in the Liver Cancer Therapeutics Market by Revenue?
The liver cancer therapeutics market covered in this report is segmented –
1) By Type: Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma, Other Types
2) By Therapy Type: Targeted Therapy, Immunotherapy, Chemotherapy, Radiation Therapy, Other Therapy Types
3) By Distribution Channel Type: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
4) By End-Users: Pediatrics, Adults
Subsegments:
1) By Hepatocellular Carcinoma: Localized Hepatocellular Carcinoma, Advanced Hepatocellular Carcinoma, Recurrent Hepatocellular Carcinoma
2) By Cholangiocarcinoma: Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma, Perihilar Cholangiocarcinoma
3) By Hepatoblastoma: Standard-Risk Hepatoblastoma, High-Risk Hepatoblastoma, Metastatic Hepatoblastoma
4) By Other Types: Fibrolamellar Carcinoma, Angiosarcoma Of The Liver, Hemangiosarcoma
What Are the Major Trends Impacting the Liver Cancer Therapeutics Market?
Major companies operating in the liver cancer therapeutics market are focusing on developing innovative therapies, such as prescription immunotherapy medications, to provide long-lasting effects. Prescription immunotherapy medications are drugs that enhance or suppress the body's immune system to help fight specific diseases, such as cancer or chronic infections, by targeting and modulating immune responses. For instance, in April 2025, Bristol Myers Squibb, a US-based biopharmaceutical company, announced the U.S. Food and Drug Administration (FDA) approval for Opdivo (nivolumab) and Yervoy (ipilimumab) for adult patients with hepatocellular carcinoma (HCC), the most prevalent primary liver cancer, that is either incurable or has spread, as a first-line treatment. The unique feature of this product lies in its approval, which is based on the results of the global Phase 3 randomized, open-label CheckMate-9DW trial. In this study, patients with metastatic or incurable HCC who had not previously had systemic therapy were randomized to receive Opdivo plus Yervoy in addition to the investigator's choice of tyrosine kinase inhibitor monotherapy (lenvatinib or sorafenib). The combination therapy demonstrated statistically significant improvements in overall survival (OS) and overall response rate (ORR) compared to the comparator arm, marking it as the only trial supporting an FDA approval that shows superior results in this setting.
Who Are the Top Companies Contributing to the Liver Cancer Therapeutics Market Expansion?
Major companies operating in the liver cancer therapeutics market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Bayer AG, Sanofi SA, Bristol-Myers Squibb, AstraZeneca PLC, Amgen Inc., Eli Lilly and Company , Gilead Sciences Inc., Regeneron Pharmaceuticals Inc., Eisai Co. Ltd., Ipsen, Exelixis Inc., BeiGene Ltd., Hutchmed, Celgene Corporation, Zymeworks Inc., Can-Fite BioPharma, Onyx Pharmaceuticals Inc.
Get the full liver cancer therapeutics market report here:
How Are Market Trends Differentiating Across Key Regions in the Liver Cancer Therapeutics Market?
North America was the largest region in the liver cancer therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the liver cancer therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
LinkedIn: The Business Research Company | LinkedIn
Comments
Post a Comment